Stockreport

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 [Seeking Alpha]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF Anzu-cel offers advantages over IOVA's Amtagvi, including less invasive cell collection, faster turnaround, and no need for high-dose IL-2. Phase 1b data show a 56% o [Read more]